Kyowa Annouces P-IIa Results of KW-6356 for Parkinson's Disorder at IAPRD
Shots:
- The controlled- randomized Ph IIa trial in 168 patients with 58 HD KW6356 group-55 LD KW-6356 group- or a 55 placebo in ratio 1:1:1- with drug administration for 12 wks
- Results: Changes from baseline in MDS-UPDRS part III showed -4.76 in HD- -5.37 in LD- and -3.14 in PBO showing KW-6356 well tolerated and effective
- Kyowa plans to initiate late Ph II trial of KW-6356 in Japan- Q4’18 for PD patient
Ref: Kyowa-Kirin | Image: BioNJ
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com